Company Insights

PLSM customer relationships

Explore interactive graphBrowse insights index
PLSM customer relationship map

Pulsenmore (PLSM): Customer relationships that underwrite a nascent commercial rollout

Pulsenmore builds and sells self-scan, connected ultrasound devices that enable at‑home prenatal and fertility monitoring; the company monetizes through device sales to health systems and channel partners, recurring services tied to remote diagnostics, and strategic commercial agreements that scale distribution into institutional payors and specialty clinics. Key near-term value drivers are institutional adoption by large HMOs and the company’s recent FDA De Novo clearance, which unlocks U.S. commercial channels and validates the product in regulated markets. For a deeper look at Pulsenmore’s customer relationships and what they mean for revenue concentration and execution risk, visit https://nullexposure.com/.

Why customers matter: institutional anchors and distribution reach

Pulsenmore’s earliest commercial traction has come through agreements with large Israeli healthcare institutions and selected U.S. partners. These relationships function as both demand anchors and go‑to‑market channels: large HMOs provide scale and order flow, while hospital partnerships and perinatal specialists give clinical credibility that eases payer conversations. Institutional customers therefore perform the dual role of revenue source and commercialization proof point.

Clalit Health Services (multiple mentions)

Pulsenmore has an ongoing commercial relationship with Clalit, Israel’s largest HMO, which has been a recurrent channel for device distribution and order backlog recognition; earlier reporting linked a Clalit orderbook to tens of thousands of units with implied revenue in the low‑single‑digit millions of dollars in specific contract windows. (Globes, FY2021; PR Newswire, Mar 2026)

According to a PR Newswire release in March 2026, Pulsenmore expanded its agreement with Clalit to supply an at‑home follicular monitoring solution for IVF and fertility preservation, signaling deeper clinical use cases beyond prenatal monitoring. (PR Newswire, Mar 2026)

Clalit health fund (historic orderbacklog reference)

An earlier Globes report from the company’s IPO period referenced a Clalit health fund agreement that created an orders backlog—tables in that reporting quantified a backlog and extrapolated revenue for delivery windows in FY2021, illustrating how Clalit commitments translated into near‑term commercial revenue when units shipped. (Globes, FY2021)

Sheba Medical Center

Sheba Medical Center has been a clinical partner using Pulsenmore devices in telemedicine and humanitarian deployments, supplying clinical validation and visibility for the product in hospital settings; Sheba’s use cases have included prenatal scans in constrained environments. (Globes, FY2022; PR Newswire, Mar 2026)

GE / GE Healthcare (strategic agreement and later termination)

Pulsenmore previously signed a strategic marketing and investment agreement with GE Healthcare that included distribution and up to $50 million in potential investment; that partnership was later terminated after regulatory timing issues around FDA approval slowed the program, demonstrating both the upside of large OEM channels and the fragility of such partnerships when regulatory timelines slip. (Globes, FY2022; Globes, FY2025 reporting)

TLC Perinatal

Pulsenmore announced a commercial engagement with TLC Perinatal in connection with its expanded U.S. commercialization after FDA De Novo clearance, which adds a specialized perinatal service provider to the company’s U.S. go‑to‑market mix and supports direct clinical channels for prenatal customers. (PR Newswire, Mar 2026)

What the relationship map implies for the business model

  • Contracting posture: Pulsenmore sells through a mix of institutional supply agreements and specialty channel partners; contracts with HMOs and hospitals suggest negotiated supply deals rather than pure transactional retail sales, which favors predictable order cadence when agreements are active.
  • Concentration and dependency: Clalit is the dominant recurring institutional partner in the public record, producing both early order backlog and ongoing commercial pilots; that concentration creates meaningful revenue leverage to a handful of institutional customers during commercialization ramp.
  • Criticality of product to customers: The devices are positioned as clinical enablers—prenatal and IVF monitoring—so for paying customers the product is operationally important and can justify negotiated procurement and integration into care pathways.
  • Maturity of relationships: Partnerships range from clinical pilots (Sheba) to commercial supply deals (Clalit) and distribution arrangements that were intended with GE; the relationship set reflects an early commercial company still converting regulatory milestones into stable, diversified revenue. No contract‑level constraints were provided in the relationship data set; this absence is itself a company‑level signal that granular contract terms are not publicly disclosed in the captured sources.

Visit https://nullexposure.com/ for a structured view of these partner engagements and how they influence commercial runway.

Investment implications and risk checklist

  • Regulatory validation drives commercial optionality. The FDA De Novo clearance referenced in Pulsenmore’s communications materially expands addressable markets and enables partnerships like TLC Perinatal in the U.S. (PR Newswire, Mar 2026).
  • Revenue concentration is a material risk. Repeated references to Clalit in the public record indicate meaningful dependence on one institutional channel for order flow and early revenue; investors should model scenarios with and without continued Clalit purchases. (Globes, FY2021; PR Newswire, Mar 2026)
  • Partner risk is real. The termination of the GE channel agreement after regulatory delay demonstrates that large OEM distribution can be conditional and sensitive to execution timelines, highlighting execution and regulatory delivery risk. (Globes, FY2022; Globes, FY2025)
  • Clinical validation and specialized channels matter. Sheba Medical Center’s clinical use and engagement with perinatal specialists provide the medical credibility necessary to convince payors and large HMOs to convert pilot programs into procurement. (Globes, FY2022; PR Newswire, Mar 2026)
  • Early‑stage financial profile. Public financial signals show zero trailing revenue, negative EBITDA, and meaningful insider ownership, which supports a thesis of high operational leverage but underlines the need for capital or stronger order conversion to reach sustainable revenues. (Company overview data, latest quarter 2025‑06‑30)

Bottom line and next actions

Pulsenmore’s customer relationships show a coherent commercial strategy: institutional HMO anchors (Clalit), hospital validation (Sheba), and targeted U.S. perinatal channels (TLC Perinatal), all amplified by regulatory progress. The company’s upside is contingent on converting institutional agreements into repeatable revenue and diversifying beyond a small number of customers; the primary downside is partner concentration and the historical sensitivity of large distribution agreements to regulatory timing.

For investors evaluating counterparty exposure and commercial execution, the practical step is to track order flow and booking disclosures tied to Clalit and new U.S. partners, and to monitor any public re‑engagements with former OEM distributors. Learn more about how these customer relationships affect commercial runway and valuation assumptions at https://nullexposure.com/.